| Date Checked | 2026-06-19 21:52:34 |
|---|---|
| Graham Number | (PB)3.33 vs (PE)0.00 |
| Over / Under Value Percentage | 167.58% vs 0.00% |
| Dividend Yield | 0.00% |
| Dividend Date | 2019-05-10 |
| Symbol | NVAX |
| AssetType | Common Stock |
| Name | Novavax Inc |
| Description | Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland. |
| CIK | 1000694 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | BIOTECHNOLOGY |
| Address | 21 FIRSTFIELD ROAD, GAITHERSBURG, MD, UNITED STATES, 20878 |
| OfficialSite | https://www.novavax.com |
| FiscalYearEnd | December |
| LatestQuarter | 2026-03-31 |
| MarketCapitalization | 1484876000 |
| EBITDA | 59532000 |
| PERatio | 0 |
| PEGRatio | 1.322 |
| BookValue | -0.88 |
| DividendPerShare | None |
| EPS | -0.56 |
| RevenuePerShareTTM | 3.669 |
| ProfitMargin | -0.147 |
| OperatingMarginTTM | -0.0719 |
| ReturnOnAssetsTTM | 0.0199 |
| ReturnOnEquityTTM | -8.98 |
| RevenueTTM | 596338000 |
| GrossProfitTTM | 163956000 |
| DilutedEPSTTM | -0.56 |
| QuarterlyEarningsGrowthYOY | -0.381 |
| QuarterlyRevenueGrowthYOY | -0.791 |
| AnalystTargetPrice | 14.11 |
| AnalystRatingStrongBuy | 0 |
| AnalystRatingBuy | 5 |
| AnalystRatingHold | 1 |
| AnalystRatingSell | 1 |
| AnalystRatingStrongSell | 2 |
| TrailingPE | - |
| ForwardPE | 2.585 |
| PriceToSalesRatioTTM | 2.391 |
| PriceToBookRatio | 33.2 |
| EVToRevenue | 1.786 |
| EVToEBITDA | 1.718 |
| Beta | 2.414 |
| 52WeekHigh | 11.97 |
| 52WeekLow | 6.13 |
| 50DayMovingAverage | 8.91 |
| 200DayMovingAverage | 8.42 |
| SharesOutstanding | 164438000 |
| SharesFloat | 141468000 |
| PercentInsiders | 5.009 |
| PercentInstitutions | 69.548 |
| ExDividendDate | None |
| naga | 1 |
| etoro | 1 |
| dateChecked | 2026-06-19 21:52:34 |
| fresh | 1 |